Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sunol Molecular Corporation
Miramar, Florida, United States
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Sunol Molecular developed novel gel therapeutics and biologic drugs targeting human tissue factor for thrombosis, single-chain T cell receptor immunoconjugates for cancer therapy, and monoclonal antibodies against Shiga toxins for bacterial infections. Its lead programs included an anti-tissue factor antibody that showed efficacy in preclinical primate models and an anti-Shiga toxin mAb that reached Phase 2 trials in South America before being discontinued. The company was acquired by Altor BioScience in 2005, which itself became part of ImmunityBio.
- Therapeutic areas
- Infectious DiseasesOncologyHematology
- Modalities
- Monoclonal antibodies (mAbs)Single-chain T cell receptors (scTCRs)
- Industry
- Biotech
Beyond the preview
Go deeper on Sunol Molecular Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sunol Molecular Corporation.